VANCOUVER, British Columbia, Jan. 07, 2026 (GLOBE NEWSWIRE) — Oroco Resource Corp. (TSX-V: OCO, OTCQB: ORRCF) (the “Company” or “Oroco”) is pleased to announce that as a result of strong investor demand, the Company has amended its agreement with Canaccord Genuity Corp. (“Canaccord Genuity”), as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters (together, the “Underwriters”), to increase the size of its previously announced bought deal public offering to aggregate gross proceeds of approximately C$20.0 million.   The Offering (as defined herein) shall consist of 52,631,600 units of the Company (the “Units”) at a price of C$0.38 per Unit (the “Offering Price”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (each whole...

New consumer bundle combines Mudra Link wristband with Rokid Glasses for touchless interaction- live demos coming to CES 2026, with launch planned for Q2 2026 Yokneam Illit, Israel, Jan. 07, 2026 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) (“Wearable Devices” or the “Company”), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, recently announced a collaboration with Rokid – a global pioneer in human-computer interaction and augmented reality, to deliver gesture control for AI and augmented reality (“AR”) glasses that feels natural, fast and consistent in daily use. Under the collaboration, Rokid Glasses (the world’s lightest full-featured AI and AR glasses) and Wearable Devices’ Mudra Link are compatible and ready for each other, with joint marketing...

HOUSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) — BlockQuarry Corp. (OTC: BLQC), a leading innovator in American-manufactured cryptocurrency mining solutions and sustainable energy infrastructure, today announced an overwhelming market response to the opening of preorders for its flagship BLQCBuster™ crypto mining platform. Following the public debut of the BLQCBuster™ at the Mining Disrupt Conference in Dallas this past November, the company has seen significant inbound interest from institutional and enterprise-scale operators. Initial feedback from the preorder launch highlights a critical market demand for domestic, high-uptime hardware. Strong Market ValidationEarly respondees to the preorder opening have expressed urgent interest in integrating the BLQCBuster’s modular architecture into existing infrastructure. Notable...

Diamond Z horizontal grinder operating at RenX’s materials processing facilityDiamond Z horizontal grinder operating at RenX’s materials processing facilityMIAMI, FL, Jan. 07, 2026 (GLOBE NEWSWIRE) — RenX Enterprises, Inc. (the “Company”) (NASDAQ: RENX), formerly known as Safe and Green Development Corporation, today announced that it has completed the purchase of a Komptech Crambo shredder and a Diamond Z horizontal grinder that had previously been deployed under a rental arrangement. The Company elected to acquire the equipment following a review of operating results demonstrating increased throughput, improved processing efficiency, and incremental revenue contribution during the rental period. A photograph of the Company’s Diamond Z horizontal grinder currently operating within RenX’s materials processing operations...

Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8, 2026. These changes reflect the Company’s focus on developing novel peptide-conjugate therapeutics through its proprietary platform that reduces the complexity of drug development and manufacturing. “Changing...

Results and Investor Q&A to Be Released in Lieu of Investor Presentation Detroit, Michigan, Jan. 07, 2026 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), a global leader in AI-driven security and productivity solutions, today announced its fiscal Q3 results are expected to be filed on January 15, 2026. Concurrently, a comprehensive investor interview featuring CEO/CTO and founder Steve Reinharz will be published that will review Q3 highlights as well as directly addressing questions raised by shareholders and market observers. The interview, conducted by SmallCapVoice, is to be released alongside the Company’s Q3 financial filing, departs from traditional executive communications by intentionally including questions that many public company executives generally do not discuss...

Also Updates Solana Holdings, Repurchases Shares TAMPA, Fla., Jan. 07, 2026 (GLOBE NEWSWIRE) — Upexi, Inc. (NASDAQ: UPXI), a leading Solana-focused digital asset treasury company and consumer brands owner, announced that it will implement a risk-adjusted high yield strategy designed to materially enhance Solana treasury returns in 2026. Upexi does not expect the implementation to cause any disruption to its Solana treasury operations. The Company believes this strategic shift will allow it to pursue improved yields in a disciplined and prudent manner, increasing operational flexibility, and strengthening alignment between treasury activities and broader corporate objectives. Upexi updated its Solana holdings, which now stand at 2,174,583 SOL as of January 5, 2026. This represents a 3.2% increase from the 2,106,989 SOL as of October...

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica has global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that the first patient was dosed in December 2025 in the global Phase 3 program evaluating YCANTH (VP-102) for the treatment of common warts. “The dosing of the first patient in the global Phase 3 program in common warts represents an important clinical milestone for our label expansion strategy...